Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

73 results about "Hepatitis b surface antigen" patented technology

Compound for inhibiting HBV transcription and hepatitis B surface antigen and application thereof

The invention belongs to the technical field of medical chemistry, and discloses a compound for inhibiting HBV transcription and hepatitis B surface antigen and application thereof. According to the invention, a small molecule compound for inhibiting HBsAg is screened from 5088 compounds by using a cell model, and a compound with a better effect is screened by screening structural analogues of the compound; the antiviral effects of the compounds are evaluated in different cell models, the compounds capable of remarkably inhibiting HBsAg are found, and the compounds 1-4 are novel potential antiviral drugs capable of inhibiting HBsAg by inhibiting HBV transcription and are expected to become novel anti-hepatitis B virus drugs.
Owner:CHONGQING MEDICAL UNIVERSITY

Vaccine for treating or preventing hepatitis B virus infection

The invention relates to the technical field of biological medicines, in particular to a vaccine for treating or preventing hepatitis B virus infection. The vaccine comprises a hepatitis B surface antigen and a composite adjuvant, wherein the composite adjuvant is prepared from CpG oligodeoxynucleotide and saponin QS-21, and the composite adjuvant is prepared from CpG oligodeoxynucleotide and saponin QS-21; the nucleotide sequence of the CpG oligodeoxynucleotide is as shown in SEQ ID NO. 1. According to the vaccine provided by the invention, an HBsAg antibody can be generated in a normal mouse body, and HBV in an HBV-carrier mouse can be effectively eliminated, so that the vaccine has the effect of treating or preventing hepatitis B virus infection. According to the vaccine provided by the invention, two adjuvants, namely CpG oligodeoxynucleotide and saponin QS-21, are adopted, so that the vaccine can be used for synergistically activating an immune effect, enhancing the activation of B cells and permanently transforming into plasma cells, and meanwhile, the vaccine can be used for resisting immune tolerance of T cells, realizing the removal of hepatitis B viruses and realizing functional cure of clinical hepatitis B treatment.
Owner:SHANDONG UNIV

Application of combination of entecavir, ASO medicine, mRNA therapeutic vaccine and / or interferon in preparation of medicine for treating chronic hepatitis B

The invention discloses an application of a combination of entecavir, an ASO drug, an mRNA therapeutic vaccine and / or interferon in preparation of drugs for treating chronic hepatitis B. Entecavir and interferon have an antiviral effect, the ASO drug reduces hepatitis B surface antigen titer, and the mRNA therapeutic vaccine is high in immunization speed, so that the entecavir, ASO drug, mRNA therapeutic vaccine and / or interferon combination can inhibit virus replication, and can be used for treating chronic hepatitis B. The composition strikes hepatitis B virus from multiple angles and multiple levels, achieves a good, lasting and non-rebound antiviral effect, and can cure hepatitis B to a certain extent.
Owner:ZHEJIANG UNIV

Antigen-antibody compound as well as preparation method and application thereof

The invention belongs to the field of biological medicines, and particularly relates to an antigen-antibody compound for enhancing immune response of hepatitis B patients as well as a preparation method and application of the antigen-antibody compound. The antigen-antibody compound preparation prepared from the HBsAg and the anti-HBsAg monoclonal antibody is superior to an antigen-antibody compound preparation prepared from a polyclonal antibody in the aspect of continuously inducing the immune response of a chronic hepatitis B patient, and an antigen-antibody compound for inducing the immune response of the hepatitis B patient is developed for the first time; in the compound, the hepatitis B surface antigen is combined with the anti-HBsAg monoclonal antibody, and the compound formed by the hepatitis B surface antigen and the anti-HBsAg monoclonal antibody in a certain mass ratio can induce immune response of chronic hepatitis B patients and can also prevent and / or treat chronic hepatitis B.
Owner:FUDAN UNIVERSITY

Anti-hepatitis B virus antibody and uses thereof

Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and / or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and / or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV.
Owner:XIAMEN UNIV +1

PAN-GENOTYPIC ASSAY AND RELATED ASPECTS FOR THE QUANTITATIVE IDENTIFICATION OF cccDNA-DERIVED OR INTEGRATED DNA-DERIVED HEPATITIS B SURFACE ANTIGEN

Provided herein are methods of detecting sources of hepatitis B virus (HBV) surface antigens (HbsAgs) in samples. Some exemplary embodiments include amplifying HBV transcript nucleic acids in or from a sample and quantifying an amount of HBV transcript nucleic acids transcribed from HBV cccDNA and an amount of HBV transcript nucleic acids transcribed from the HBV iDNA. Related systems and other aspects are also provided.
Owner:JOHNS HOPKINS UNIVERSITY

Preparation and use of aluminum hydroxide oxide nano-adjuvant based on calcium or silicon doping

PCT designated stage expiredWO2025112290A1SsRNA viruses positive-senseViral antigen ingredientsAdjuvantAluminum oxide hydroxide
A preparation method for and the use of an aluminum hydroxide oxide nano-adjuvant based on calcium and silicon doping. The particle morphology of the AlOOH adjuvant is a 50-800 nm nano-particle, wherein silicon or calcium is doped in AlOOH crystal lattices, and the molar ratio of calcium or silicon to aluminum is 0.01-100:1. The preparation method comprises: synthesizing AlOOH by using an Al source, doping Ca or Si in a reaction solution by using a calcium source or a silicon source, precipitating Al(OH)3 and a dopant by adding an alkaline solution, and preparing a Ca- or Si-doped AlOOH adjuvant by means of a hydrothermal synthesis method. In a hepatitis B surface antigen and varicella-zoster virus glycoprotein E antigen model, the calcium- or silicon-doped AlOOH nano-adjuvant can simultaneously induce efficient humoral immunity and cellular immunity by means of in-vivo experiment verification of mice.
Owner:DALIAN UNIV OF TECH

HBsAg Detection Method and Related Equipment Based on Multiple Wavelengths

The present invention provides a multi-wavelength-based HBsAg detection method, including: detecting the light absorption value of a sample to be tested for HBsAg by a sandwich ELISA method using a multi-wavelength microplate reader to obtain the light absorption data of the sample to be tested for HBsAg at multiple wavelengths; determining the OD value of the sample, the OD value of the negative control, and the OD value of the positive control at dual wavelengths based on the light absorption data at wavelengths of 450 nm and 630 nm; determining whether the first detection result is valid within the preset concentration range of HBsAg based on the OD value of the negative control and the OD value of the positive control; if the first detection result is invalid within the preset concentration range of HBsAg, determining the second detection result of the sample to be tested for HBsAg based on the mapping relationship between the light absorption data at multiple wavelengths and the detection result of chemiluminescence method. The present invention improves the sensitivity, accuracy, and reliability of hepatitis B surface antigen detection at low concentrations.
Owner:贵州航天医院 +1

Ldh-based vaccine adjuvant, and preparation method and application thereof

The application discloses an LDH-based vaccine adjuvant and a preparation method and application thereof, and belongs to the technical field of aluminum adjuvant preparation of vaccines, and the preparation method comprises the following steps: mixing at least one of soluble magnesium salt, soluble zinc salt, soluble manganese salt and soluble calcium salt with soluble aluminum salt, and then performing a co-precipitation reaction with a sodium hydroxide aqueous solution in a colloid mill device, and performing crystallization to obtain LDH nanosheets; dispersing the LDH nanosheets in a PBS solution, adding a hepatitis B surface antigen molecule drug, uniformly mixing, and then performing centrifugation to obtain the LDH-based vaccine adjuvant. The LDH-based vaccine adjuvant can significantly promote the maturation of DC cells and the activation of T cells, and the total IgG level reflects the overall humoral immune response intensity of the body to vaccines or pathogens; the LDH-based vaccine adjuvant forms a "storage library" at an injection site to store antigens and slowly release the antigens, and the purpose of long-time continuous stimulation of the immune system in the body is achieved.
Owner:BEIJING UNIV OF CHEM TECH

Use of ciprofibrate in the preparation of a drug for anti-hepatitis B virus

The present invention relates to the use of ciprofibrate in the preparation of a drug for anti-hepatitis B virus, belonging to the field of biomedical technology. The present invention provides the use of ciprofibrate in the preparation of a drug for anti-hepatitis B virus. Ciprofibrate reduces the expression levels of hepatitis B surface antigen HBsAg, hepatitis B e antigen HBeAg, and hepatitis B core antigen HBcAg in human primary cells infected with hepatitis B virus, inhibits hepatitis B virus from infecting cells, inhibits the proliferation and replication of hepatitis B virus, can protect neonatal hepatocytes from being reinfected, has an anti-hepatitis B virus effect, and thus prevents and treats diseases caused by hepatitis B virus. Ciprofibrate, as a lipid-regulating drug, has minor side effects, does not require subcutaneous injection, and has high patient compliance.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Treatment of hepatitis

Provided herein are methods of treating hepatitis B and / or hepatitis D using a Na + / taurocholic acid co-transporter polypeptide (NTCP) inhibitor (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or a compound of Formula (II) or a pharmaceutically acceptable salt thereof). Such methods may include reducing the concentration of hepatitis B DNA, reducing the concentration of hepatitis D DNA, reducing hepatitis B surface antigen, and reducing hepatitis B core antigen (HBcAg).
Owner:ALBIREO

Bipyrimidine heterocyclic compound as well as preparation method and application thereof

The invention discloses a bipyrimidine heterocyclic compound and a preparation method and application thereof, the bipyrimidine heterocyclic compound has a structure as shown in a formula (I), and the invention also provides a pharmaceutical composition containing the compound or a stereoisomer, a medicinal salt, a hydrate, a solvate or a crystal thereof. The invention also discloses application of the compounds in preparation of drugs for treating hepatitis B virus infection, and particularly the compounds can be used as PAPD5 / 7 enzyme inhibitors and hepatitis B RNA non-stabilizers for treating hepatitis B viruses. The compound provided by the invention has the characteristics that the concentration of hepatitis B surface antigen and hepatitis B DNA and RNA can be remarkably reduced, and the probability of functional healing of hepatitis B can be remarkably improved by clinically combining with nucleoside drugs, oligonucleotide drugs / PD-L1 compounds and the like.
Owner:SUZHOU MEDNES PHARMA TECH CO LTD

Affinity resins for the purification of hepatitis b surface antigen

Provided are affinity ligands that bind to Hepatitis B surface antigen (HBsAg), affinity resins comprising the HBsAg-binding ligands, and related compositions and methods for the isolation and / or purification of HBsAg.
Owner:REPLIGEN CORP

Malaria vaccine

The invention relates to a composition comprising a polypeptide comprising, or consisting of, the amino acid sequence of SEQ ID) NO: 1, or a sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to SEQ ID NO: 1 (R21), wherein said polypeptide is in the form of a virus-like particle (VLP), wherein said particle comprises less than 10% free hepatitis B surface antigen protein, for use in the immunisation of a human subject susceptible to Plasmodium falciparum infection, characterised in that said composition is administered in a dosage regimen of at least one dose of 1 μg to 20 μg R21 per administration for a subject at least 18 years old, or at least one dose of 0.5 μg to 10 μg R21 per administration for a subject less than 18 years old. The invention also relates to kits, methods and uses.
Owner:OXFORD UNIVERSITY INNOVATION LTD

Cellulose-based affinity membrane for hepatitis b virus and preparation method and application thereof

PendingCN122273330AAntigenHepatitis B virus
This invention belongs to the field of affinity membrane and bioseparation technology, and provides a cellulose-based affinity membrane for hepatitis B virus (HBV), its preparation method, and its application. The affinity membrane consists of a base membrane and an affinity ligand immobilized on the base membrane. The base membrane is a carboxylated cellulose filter membrane or a carboxylated modified cellulose filter membrane. The affinity ligand is a biomolecule that specifically recognizes HBV surface antigen. The carboxyl groups of the base membrane and the amino groups of the affinity ligand are linked by amide bonds. Unreacted carboxyl groups on the base membrane are blocked by a blocking reagent. The carboxyl content of the base membrane is 400-1000 μmol / g, the pore size is 400-1000 nm, and the porosity is 30%-60%. The application refers to the use of the above-mentioned affinity membrane in the specific clearance of HBV from HBV-positive plasma. This invention can achieve efficient and specific clearance of HBV from plasma, maximally preserving the activity and function of normal plasma components, and improving the feasibility of industrial application.
Owner:DALIAN UNIV OF TECH

Application of ACSS2 as hepatitis B treatment target

The invention discloses application of ACSS2 as a target spot in screening of drugs for treating hepatitis B virus infectious diseases or symptoms, and application in screening of products for inhibiting hepatitis B surface antigens or screening of products for inhibiting HBV transcription and replication. The invention also discloses application of the ACSS2 expression promoter in preparation of drugs for treating hepatitis B virus infectious diseases or symptoms. The invention also provides a pharmaceutical composition for treating hepatitis B virus infectious diseases or symptoms or resisting hepatitis B viruses, and the pharmaceutical composition contains the ACSS2 expression promoter serving as an active ingredient and a pharmaceutically acceptable carrier. The invention provides a new potential target for treating hepatitis B, provides a new treatment strategy for clinical treatment, and has wide application prospect and market potential.
Owner:CHONGQING MEDICAL UNIVERSITY

Vaccine composition against coronavirus

The present invention relates to: a conjugate in which a receptor-binding domain (RBD) of coronavirus and a hepatitis B surface antigen (HBsAg) are linked; virus-like particles including the conjugate; and a coronavirus vaccine composition containing the conjugate and / or virus-like particles.
Owner:LG CHEM LTD

SARS-COV-2 spike fused to a hepatitis b surface antigen

Provided herein are nucleic acid molecules encoding a SARS-CoV-2 S ectodomain—HBsAg fusion protein. When expressed in mammalian cells (for example, by administration to a mammalian subject), the fusion protein self-assembles to form a HBsAg protein nanoparticle with SARS-CoV-2 S ectodomain trimers extending radially outward from an outer surface of the HBsAg protein nanoparticle. Thus, in several aspects, the disclosed nucleic acid molecule can be used to generate an immune response to SARS-CoV-2 in a subject.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Application of BTLA inhibitor in preparation of medicine for preventing and / or treating chronic hepatitis B

The invention provides application of a BTLA inhibitor in preparation of a medicine for preventing and / or treating chronic hepatitis B, and belongs to the technical field of biological medicine. Research finds that antagonistic B and T lymphocyte attenuation factors (BTLA) can promote removal of hepatitis B surface antigen (HBsAg), reduce the expression level of HBeAg, promote activation and proliferation of T cells and enhance host immune response, so that the purpose of preventing and / or treating chronic hepatitis B is achieved, and functional cure of chronic hepatitis B (CHB) is achieved. The invention provides more choices for medicines for clinically preventing and / or treating chronic hepatitis B.
Owner:QUAN ZHOU SHI DI YI YI YUAN

Compounds inhibiting hepatitis b surface antigen and uses thereof

The application belongs to the technical field of pharmaceutical chemistry, and discloses a compound for inhibiting hepatitis B surface antigen and application thereof. It is proved through research that the recombinant plasmid S-HiBiT constructed can characterize the expression and secretion of HBs, and can be used for screening the compound for inhibiting HBs, and a cell model for screening anti-HBV drugs targeting HBsAg, i.e. HepG2-PB-S-HiBiT stable expression cell line. It is verified through experiments that the model is particularly suitable for high-throughput screening of compounds. Compound 1 and compound 3 capable of inhibiting HBsAg are found through screening of a compound library by using the model, the drug has the potential to be further developed into a hepatitis B treatment candidate drug, and a new drug is provided for the treatment of hepatitis B.
Owner:重庆医科大学国际体外诊断研究院

Oral vaccine for hepatitis b

An oral vaccine for Hepatitis B is disclosed. The oral vaccine for Hepatitis B includes a delivery platform including Arthrospira platensis with a plurality of host genomes and a plurality of Hepatitis B surface antigen delivery vectors coupled to the plurality of host genomes. Each Hepatitis B surface antigen delivery vector of the plurality of Hepatitis B surface antigen delivery vectors has a nucleotide sequence identical to nucleotide sequence of SEQ ID NO. 2. Each respective Hepatitis B surface antigen delivery vector of the plurality of Hepatitis B surface antigen delivery vectors includes at least one surface antigen of Hepatitis B with a weight ratio of the delivery platform to the at least one surface antigen of Hepatitis B in a range of 1: 10-4 to 1: 2x10- 3 (delivery platform: at least one surface antigen of Hepatitis B).
Owner:ABDALI NARGESS

HBsAg Detection Method and Related Equipment Based on Multiple Wavelengths

The present invention provides a multi-wavelength-based HBsAg detection method, including: detecting the optical absorption value of a sample to be detected for HBsAg by a sandwich immunoassay using a multi-wavelength microplate reader to obtain the optical absorption data of the sample to be detected for HBsAg at multiple wavelengths; determining the OD value of the sample, the OD value of the negative control, and the OD value of the positive control at two wavelengths based on the optical absorption data at 450 nm and 630 nm wavelengths; determining whether the first detection result is valid within the preset concentration range of HBsAg based on the OD value of the negative control and the OD value of the positive control; if the first detection result is invalid within the preset concentration range of HBsAg, determining the second detection result of the sample to be detected for HBsAg based on the mapping relationship between the optical absorption data at multiple wavelengths and the detection result of chemiluminescence method. The present invention improves the sensitivity, accuracy, and reliability of the detection of hepatitis B surface antigen at low concentrations.
Owner:贵州航天医院 +1

Construction of hepatitis b surface antigen-specific b cell receptor gene knock-in mouse model

The application discloses a hepatitis B surface antigen specific B cell receptor gene knock-in mouse model, and establishes a hepatitis B virus surface antigen (HBsAg) specific B cell receptor (BCR) gene knock-in mouse model, wherein 70-90% of B cells of the mouse can specifically recognize HBsAg, and differentiate into germinal center B cells and plasma cells. Therefore, the model can be used for basic research on hepatitis B antiviral humoral immune response and tolerance mechanism, and can also be used for application research on development of drugs and vaccines for breaking HBsAg immune tolerance. In summary, the establishment of the model lays a solid foundation for development of a functional cure immune means for hepatitis B.
Owner:FUDAN UNIVERSITY

HBsAg detection method based on multiple wavelengths and related equipment

The invention provides a multi-wavelength-based HBsAg detection method, which comprises the following steps: carrying out light absorption value detection on an HBsAg sample to be detected by a double-antibody sandwich method through a multi-wavelength microplate reader to obtain light absorption data of the HBsAg sample to be detected under multiple wavelengths; based on the light absorption data under the wavelength of 450 nm and the wavelength of 630 nm, determining a sample OD value, a negative control OD value and a positive control OD value under dual wavelengths; based on the negative control OD value and the positive control OD value, determining whether the first detection result is effective in a preset concentration range of HBsAg; and if the first detection result is invalid in the preset concentration range of HBsAg, determining a second detection result of the HBsAg sample to be detected based on a mapping relationship between the light absorption data under multiple wavelengths and a chemiluminescence method detection result. According to the invention, the sensitivity, accuracy and credibility of low-concentration hepatitis B surface antigen detection are improved.
Owner:贵州航天医院 +1

METHOD FOR REDUCING HEPATITIS B VIRUS SURFACE ANTIGEN (HBsAg) AND HEPATITIS B DRUG FOR USE IN THE METHOD

There is provided a method of curing chronic hepatitis B infection in a human, the method comprising administering to a subject in need thereof an effective amount of one or both of an exogenous anti-HBs antibody or an anti-HBs antibody producing carrier, the present invention relates to a method for reducing cellular and blood hepatitis B surface antigen (HBsAg) by providing continuously increased levels of anti-HBs antibodies in the subject.
Owner:HBV TECH CO LTD

Hepatitis B immune regimens and compositions

PendingCN119607192AViral antigen ingredientsVirus peptidesHepatitis B virus core AntigenAdjuvant
The present invention relates to hepatitis B immune regimens and compositions. The present invention provides a method of treating chronic hepatitis B infection (CHB) in a human comprising the steps of: a) administering to the human a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector, the replication-deficient chimpanzee adenovirus (ChAd) vector comprises a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a modified vaccinia virus Ankara (MVA) vector, the modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B virus core antigen (HBc) and an adjuvant.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA

Matrine type alkaloid SA as well as preparation method and application thereof

The invention discloses matrine type alkaloid SA as well as a preparation method and application thereof, and belongs to the field of traditional Chinese medicine preparation. The matrine type alkaloid with a new structure is extracted from sophora moorcroftiana, and cell experiments find that the matrine type alkaloid not only has the effect of resisting hepatitis B virus (HBV), but also has the inhibitory effect on hepatitis B surface antigen (HBsAg) superior to that of matrine and oxymatrine of the same kind, and also superior to that of lamivudine. Therefore, the matrine type alkaloid can be used for preparing the medicine for treating or preventing hepatitis B virus (HBV) infection.
Owner:KUNMING UNIV OF SCI & TECH

Peanut seed specific gene promoter N1YYK3 and application thereof

The invention provides a peanut seed specific gene promoter N1YYK3 and application thereof, and relates to the technical field of plant genetic engineering. The promoter N1YYK3 is selected from SEQ ID NO.01, a sequence which is reversely complementary with the SEQ ID NO.01, SEQ ID NO.02, a DNA (deoxyribonucleic acid) or RNA (ribonucleic acid) sequence which is hybridized with the SEQ ID NO.01 or the SEQ ID NO.02, a sequence which is at least 95% consistent with the sequence of the SEQ ID NO.01 or the SEQ ID NO.02, and a DNA or RNA sequence which is complementary with any one of the SEQ ID NO.01 and the SEQ ID NO.02; the promoter 0B3TGP can be utilized or operated to drive the hepatitis B surface antigen HBsAg gene in peanut seed tissue cells to express and efficiently produce the hepatitis B surface antigen HBsAg vaccine.
Owner:海南弥生生物科技有限公司 +1

Hepatitis b pre s1 antigen, its preparation method and application

ActiveCN120058875BNo biosecurity riskstable sourceHev antigenAnti antibody
The present application relates to the technical field of immunological detection, in particular to hepatitis B PreS1 antigen and its preparation method and application. The present application first selects an active PreS1 polypeptide sequence, which is coupled to a hepatitis B surface antigen HBsAg molecule through a crosslinking agent to obtain a hepatitis B PreS1 antigen having both hepatitis B surface antigen activity and PreS1 antigen activity, which can be used as a calibrator and positive control in a hepatitis B PreS1 antigen detection kit. The kit uses anti-PreS1 antibody as coating and anti-HBsAg antibody as enzyme label. The artificial coupled hepatitis B PreS1 antigen prepared by the present application can effectively replace the currently used PreS1 real positive sample on the market, has no biological safety risk, stable source, and various indexes such as reactivity, vehicle stability and thermal stability, which are all better than those of the real positive sample, and has high innovation and applicability.
Owner:ZHENGZHOU IMMUNO BIOTECH